Clinical Trials Logo

Filter by:
  • None
  • Page [1]
NCT ID: NCT03369314 Recruiting - Clinical trials for Thrombotic Thrombocytopenic Purpura

Observational Study of the Use of octaplasLG®.

Start date: December 2017
Phase: N/A
Study type: Observational

This observational study enrolls patients who have received at least one infusion of octaplasLG®. OctaplasLG® will be administered standard of care and observation occurs during the treatment and 24 hours after the end of treatment. Characteristics of the use of octaplasLG®, tolerance criteria, and efficacy criteria will be collected.

NCT ID: NCT02188862 Completed - Clinical trials for Rheumatic Heart Disease

Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region

Start date: September 2012
Phase: N/A
Study type: Observational

The purpose of this study is to investigate whether there are genetic differences between patients with rheumatic heart disease and members of the general population.

NCT ID: NCT00853762 Terminated - Clinical trials for Relapsing Multiple Sclerosis

Atacicept in Multiple Sclerosis Extension Study, Phase II

Start date: February 2009
Phase: Phase 2
Study type: Interventional

This study, 28851, is a long-term follow-up study of subjects enrolled in ATAMS study 28063, the aim of which is to monitor the safety and tolerability of atacicept administered for up to 5 years to subjects with relapsing multiple sclerosis (RMS). This extension study consists of two parts. Part A will be double blind and Part B will be open label. During Part A subjects initially randomized to atacicept will continue to receive the atacicept dose to which they have been randomized in study 28063 (ATAMS) once a week sub cutaneously (under the skin). Subjects randomized to placebo in ATAMS will receive atacicept at 150 mg once a week sub cutaneously during Part A. Once the results of ATAMS are available and the atacicept dose with the best benefit / risk ratio has been identified, all subjects will be switched to this dose and will continue the extension study open-label (Part B). Throughout the study, subjects and investigators will remain blinded with respect to intial and part A treatment allocation/dose.